Pharmacokinetic and pharmacodynamic properties of a new biosimilar filgrastim TPI G-CSF in comparison to the marketed reference filgrastim Neupogen®: a double-blind, single-dose, two-period crossover trial
作者： Andrew Bourgoin , Sarfaraz Niazi
DOI: 10.2147/BS.S86638
关键词:
摘要:
sci-hub.se 参考文章(18)
Heinz Lubenau, Peter Bias, Anne-Katrin Maly, Karl Ernst Siegler, Kai Mehltretter, Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen® BioDrugs. ,vol. 23, pp. 43- 51 ,(2009) , 10.2165/00063030-200923010-00005
Bing Wang, Thomas M. Ludden, Ellen N. Cheung, Gisela G. Schwab, Lorin K. Roskos, Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 28, pp. 321- 342 ,(2001) , 10.1023/A:1011534529622
Alan C. Herman, Thomas C. Boone, Hsieng S. Lu, Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. Pharmaceutical biotechnology. ,vol. 9, pp. 303- 328 ,(2002) , 10.1007/0-306-47452-2_7
Preeta Chugh, Vandana Roy, Biosimilars: current scientific and regulatory considerations. Current Clinical Pharmacology. ,vol. 9, pp. 53- 63 ,(2014) , 10.2174/15748847113089990066
MH Bronchud, MR Potter, G Morgenstern, MJ Blasco, JH Scarffe, N Thatcher, D Crowther, LM Souza, NK Alton, NG Testa, TM Dexter, In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. British Journal of Cancer. ,vol. 58, pp. 64- 69 ,(1988) , 10.1038/BJC.1988.163
Fritz Sörgel, Arnd Schwebig, Johann Holzmann, Stefan Prasch, Pritibha Singh, Martina Kinzig, Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics BioDrugs. ,vol. 29, pp. 123- 131 ,(2015) , 10.1007/S40259-015-0124-7
Cornelius F. Waller, Miguel Bronchud, Stuart Mair, Rodeina Challand, Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial Annals of Hematology. ,vol. 89, pp. 927- 933 ,(2010) , 10.1007/S00277-010-0961-X
Athanasia D. Panopoulos, Stephanie S. Watowich, Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis Cytokine. ,vol. 42, pp. 277- 288 ,(2008) , 10.1016/J.CYTO.2008.03.002
Hans Wildiers, Marcel Reiser, Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma Critical Reviews in Oncology Hematology. ,vol. 77, pp. 221- 240 ,(2011) , 10.1016/J.CRITREVONC.2010.02.002
Janelle M. Fauci, Jenny M. Whitworth, Kellie E. Schneider, Akila Subramaniam, Bin Zhang, Peter J. Frederick, Larry C. Kilgore, J. Michael Straughn, Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer Gynecologic Oncology. ,vol. 122, pp. 532- 535 ,(2011) , 10.1016/J.YGYNO.2011.05.023